TP53 and myeloid neoplasm: Mutations including TP53, TET2, DNMT3A, and ASXL1 are frequently detected before treatment, among which TP53 and TET2 showed significant expansion after sMN development, which are not only related to the pathogenesis of myeloid neoplasms, but also portend a poor prognosis (52).